270: Your guide to Wegovy’s blockbuster heart study
The Readout Loud
00:00
The Future of Lilly's Drugs
Lilly is working on a subcutaneous version of an anti amyloid antibody. The drug could conceivably, if it succeeds in clinical trials, be available on the market before denanamab's patents run out. And likewise, with Mount Jaro, they're going to continue to innovate around obesity drugs.
Transcript
Play full episode
